BofA raised the firm’s price target on Argenx (ARGX) to $1,006 from $942 and keeps a Buy rating on the shares. Argenx remains one of the analyst’s top picks for 2026 as the firm thinks focus will remain on the commercial launch of Vyvgart in gMG and CIDP, but it sees opportunities for upside from “myriad data catalysts in 2026.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target raised to $1,160 from $1,085 at Guggenheim
- Argenx downgraded to Neutral from Outperform at Baird
- argenx: Strong Growth and Pipeline Potential Already Priced In, Warranting a Neutral/Hold Rating
- Argenx Moves Ahead With Its Phase 2 Study on ARGX-119 for Pediatric SMA
- Argenx price target raised to $925 from $860 at RBC Capital